Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis

Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’

Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials

Emmes partners with Miimansa AI to accelerate adoption of Generative AI in clinical research

The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data

Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug

Shilpa Biologicals receives registration approval for Adalimumab from Morocco, MoH

Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)

Torrent Pharmaceuticals posts Q1 FY25 consolidated PAT at Rs. 457 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024

Zydus receives USFDA’s final approval for Valsartan Tablets

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India

Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau

The inspections concluded with no Form 483 observations or significant critical findings

Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr

Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024